PRLD

Prelude Therapeutics Incorporated · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-10

Figures on this page computed 2026-11-08 12:48 UTC

Last close

4.08USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-10

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
The filing itself
-819.6%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
-464.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
0.26Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.15 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.27x

1.18x

0.85x

1.90x

0.36x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-10

Sales1.27x
Its own average over 2 years, 9.6M.
Profit1.18x
Its own average over 8 years, -84.4M.
Free cash flow0.85x
Its own average over 8 years, -66.2M.
Debt1.90x
Its own average over 6 years, 9.4M.
Price0.36x
Its own average over 7 years, 11. Market data, 2026-11-04

Debt is furthest from its own average, at 1.90 times.

Sales is 1.27 times its own 2-year average; Profit is 1.18 times its own 8-year average; Free cash flow is 0.85 times its own 8-year average; Debt is 1.90 times its own 6-year average; Price is 0.36 times its own 7-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-10

Sales against its own 2-year average1.27
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
The filing itself
Profit against its own 8-year average1.18
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
The filing itself
Free cash flow against its own 8-year average0.85
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
The filing itself
Debt against its own 6-year average1.90
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
The filing itself
Price against its own 7-year average0.36Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD